Holen Sie sich die Stockscreener-App
1.405
12.73%
-0.205
Handel nachbörslich:
1.44
0.035
+2.49%
Schlusskurs vom Vortag:
$1.61
Offen:
$1.59
24-Stunden-Volumen:
98,397
Relative Volume:
1.08
Marktkapitalisierung:
$66.22M
Einnahmen:
$18.11M
Nettoeinkommen (Verlust:
$-18.95M
KGV:
-3.2114
EPS:
-0.4375
Netto-Cashflow:
-
1W Leistung:
-21.07%
1M Leistung:
-29.40%
6M Leistung:
-12.19%
1J Leistung:
-54.38%
1-Tages-Spanne:
$1.30
$1.70
1-Wochen-Bereich:
$1.30
$1.80
52-Wochen-Spanne:
$1.30
$3.16
Adagene Inc Adr Stock (ADAG) Company Profile
Vergleichen Sie ADAG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAG
Adagene Inc Adr
|
1.405 | 75.88M | 18.11M | -18.95M | 0 | -0.4375 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.47 | 105.61B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
657.53 | 67.99B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
442.70 | 58.19B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
854.65 | 52.40B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.70 | 39.60B | 447.02M | -1.18B | -906.14M | -6.1812 |
Adagene Inc Adr Stock (ADAG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-06 | Eingeleitet | Leerink Partners | Outperform |
| 2025-01-31 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-06-25 | Eingeleitet | China Renaissance | Buy |
| 2021-03-08 | Eingeleitet | Goldman | Buy |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Adagene Inc Adr Aktie (ADAG) Neueste Nachrichten
Why Adagene Inc. Depositary Receipt stock is a must watch in 2025Weekly Loss Report & Reliable Trade Execution Plans - newser.com
What’s the recovery path for long term holders of Adagene Inc. Depositary ReceiptExit Point & High Win Rate Trade Alerts - newser.com
Adagene Inc. Depositary Receipt stock daily chart insightsQuarterly Earnings Summary & Target Return Focused Stock Picks - newser.com
Understanding Adagene Inc. Depositary Receipt’s price movement2025 Market Outlook & Community Supported Trade Ideas - newser.com
Adagene doses first patient in Phase 2 trial of muzastotug for MSS CRC - Investing.com India
Adagene Inc. Initiates Phase 2 Clinical Trial of Muzastotug in Combination with KEYTRUDA for Colorectal Cancer - Quiver Quantitative
Adagene Announces First Patient Dosed in Randomized Dose - GlobeNewswire
Adagene (NASDAQ:ADAG) Given "Sell (D-)" Rating at Weiss Ratings - MarketBeat
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Grows By 66.4% - Defense World
CEO Change: Why analysts raise outlook for Adagene Inc. (Common Stock) (978) stockForecast Cut & High Accuracy Swing Entry Alerts - Trung tâm Dự báo KTTV quốc gia
Will Adagene Inc. Depositary Receipt stock recover faster than marketDip Buying & Safe Entry Trade Signal Reports - nchmf.gov.vn
Chart based analysis of Adagene Inc. Depositary Receipt trendsBreakout Watch & Advanced Swing Trade Entry Plans - newser.com
Weiss Ratings Reaffirms Sell (D-) Rating for Adagene (NASDAQ:ADAG) - MarketBeat
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Up 320.2% in September - Defense World
Adagene Inc. (ADAG) stock price, news, quote and history - Yahoo! Finance UK
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Sees Significant Increase in Short Interest - MarketBeat
All You Need to Know About Adagene (ADAG) Rating Upgrade to Buy - Yahoo Finance
How sentiment analysis helps forecast Adagene Inc. Depositary ReceiptMarket Growth Review & AI Driven Price Forecasts - newser.com
Are Medical Stocks Lagging Adagene (ADAG) This Year? - sharewise.com
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Update - MarketBeat
Lucid Capital Markets initiates coverage on Adagene stock with Buy rating - Investing.com India
Adagene Inc. Amends Collaboration Agreement with Exelixis to Advance SAFEbody Technology for Cancer Therapy - Quiver Quantitative
Adagene Expands SAFEbody® Collaboration and License - GlobeNewswire
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked Antibody-Drug Conjugate - MarketScreener
Breakthrough Cancer Drug Technology: Adagene's 'Invisible' ADC Platform Expands to Third Program - Stock Titan
Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Short Interest Down 38.1% in August - Defense World
Using economic indicators to assess Adagene Inc. Depositary Receipt potential2025 Historical Comparison & Verified Short-Term Plans - newser.com
Quantitative breakdown of Adagene Inc. Depositary Receipt recent moveProduct Launch & High Return Trade Opportunity Guides - Newser
Adagene to present new ADG126 clinical data at ASCO-GI - MSN
Using data tools to time your Adagene Inc. Depositary Receipt exit2025 Historical Comparison & Risk Controlled Stock Pick Alerts - Newser
Is Adagene (ADAG) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Short Interest in Adagene Inc. Sponsored ADR (NASDAQ:ADAG) Drops By 70.6% - MarketBeat
Adagene’s ADG126 to be Highlighted in Two Presentations at - GlobeNewswire
Adagene’s ADG126 to be Highlighted in Two Presentations at the 2025 Chinese Society of Clinical Oncology (CSCO) Meeting in Jinan, China - The Manila Times
Adagene Inc. Showcases ADG126 at CSCO Meeting with Promising Results in Advanced MSS Colorectal Cancer - Quiver Quantitative
30% Response Rate: Adagene's Novel Cancer Drug Shows Promise in Hard-to-Treat Colorectal Cancer Trial - Stock Titan
Former YERVOY developer Axel Hoos joins Adagene as advisor - Investing.com
Adagene Inc. Appoints Dr. Axel Hoos as Executive Advisor to Enhance Immuno-Oncology Initiatives - Quiver Quantitative
Adagene Appoints Immuno-Oncology Pioneer, Axel Hoos, M.D., Ph.D., as Executive Advisor - The Manila Times
Former $2.5B Scorpion CEO & YERVOY Developer: Adagene's CTLA-4 Platform Could Transform Cancer Care - Stock Titan
Is Adagene Inc. Depositary Receipt’s growth already priced inJuly 2025 Big Picture & Real-Time Buy Zone Alerts - خودرو بانک
Can Adagene Inc. Depositary Receipt maintain sales growthJuly 2025 Drop Watch & Free Real-Time Market Sentiment Alerts - خودرو بانک
What data driven models say about Adagene Inc. Depositary Receipt’s futureWeekly Stock Recap & Weekly High Momentum Picks - Newser
Adagene to Participate in Two Investor Conferences in September - The Manila Times
Biotech Innovator Adagene Scheduled for Major Wall Street Healthcare Conferences in September 2025 - Stock Titan
Will Adagene Inc. Depositary Receipt see short term momentumTrade Performance Summary & Smart Swing Trading Techniques - Newser
Is Adagene (ADAG) Outperforming Other Medical Stocks This Year? - Yahoo Finance
What moving averages say about Adagene Inc. Depositary ReceiptWeekly Profit Analysis & Daily Chart Pattern Signal Reports - Newser
Finanzdaten der Adagene Inc Adr-Aktie (ADAG)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.44%
0.70%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):